hVIVO (LON:HVO) Receives “Add” Rating from Peel Hunt

Peel Hunt reissued their add rating on shares of hVIVO (LON:HVO) in a research note published on Tuesday, MarketBeat.com reports. The brokerage currently has a GBX 10 price target on the stock.

Separately, Shore Capital decreased their price target on hVIVO from GBX 35 to GBX 25 and set a “buy” rating on the stock in a research note on Tuesday, September 23rd. Two investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of GBX 17.50.

hVIVO Stock Performance

hVIVO stock opened at GBX 6.39 on Tuesday. The firm has a fifty day simple moving average of GBX 7.81 and a two-hundred day simple moving average of GBX 10.69. The company has a quick ratio of 1.16, a current ratio of 1.61 and a debt-to-equity ratio of 33.86. hVIVO has a twelve month low of GBX 6.20 and a twelve month high of GBX 29.80. The company has a market capitalization of £43.88 million, a PE ratio of 8.29 and a beta of 0.97.

hVIVO (LON:HVO) last announced its quarterly earnings data on Tuesday, September 23rd. The company reported GBX (0.29) earnings per share (EPS) for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. Research analysts expect that hVIVO will post 1.5492958 EPS for the current year.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.